论文部分内容阅读
据德国慕尼黑Munchen技术大学的研究人员们报道,在手术前的化疗期间,应用18F-脱氧葡糖(18FDG)的正电子发射断层摄影术(PET)成像测定代谢功能可以及早地辨别出局部晚期胃癌患者是否对术前化疗产生反应。一个可以预示治疗反应的诊断结果对胃癌患者今后是否选用术前化疗非常关键,而FDG-PET的应用则能潜在地预测患者早期治疗结果。在一项手术前接受化疗的44例局部晚期胃癌患者的前瞻性研究中,Katya Ott博士及其同事根据治疗引起的FDG摄入减少的预测值来评估患者的后期反应及其生存情况。试验中,研究人员分别在试验初期(基线)和
Researchers at the Munchen University of Technology in Munich, Germany, reported that the use of 18F-deoxyglucose (18FDG) positron emission tomography (PET) imaging to measure metabolic function during preoperative chemotherapy can early identify locally advanced gastric cancer Does the patient respond to preoperative chemotherapy? A diagnosis that predicts response to treatment is crucial for the future use of preoperative chemotherapy in patients with gastric cancer, whereas the use of FDG-PET potentially predicts early treatment outcomes in patients. In a prospective study of 44 patients with locally advanced gastric cancer who underwent chemotherapy prior to surgery, Dr. Katya Ott and colleagues evaluated late-stage response and survival in patients based on the predictive value of treatment-induced decrease in FDG intake. In the experiment, researchers at the beginning of the experiment (baseline) and